Vis enkel innførsel

dc.contributor.authorLogallo, Nicolaen_US
dc.contributor.authorNæss, Halvoren_US
dc.contributor.authorIdicula, Titto T.en_US
dc.contributor.authorBrøgger, Jan C.en_US
dc.contributor.authorWaje-Andreassen, Ulrikeen_US
dc.contributor.authorThomassen, Larsen_US
dc.date.accessioned2012-01-24T08:51:11Z
dc.date.available2012-01-24T08:51:11Z
dc.date.issued2011-09-25eng
dc.PublishedBMC Neurology 2011, 11:114en
dc.identifier.issn1471-2377
dc.identifier.urihttps://hdl.handle.net/1956/5509
dc.description.abstractBackground: A possible synergic role of serum uric acid (SUA) with thrombolytic therapies is controversial and needs further investigations. We therefore evaluated association of admission SUA with clinical improvement and clinical outcome in patients receiving rt-PA, early admitted patients not receiving rt-PA, and patients admitted after time window for rt-PA. Methods: SUA levels were obtained at admission and categorized as low, middle and high, based on 33° and 66° percentile values. Patients were categorized as patients admitted within 3 hours of symptom onset receiving rt-PA (rt-PA group), patients admitted within 3 hours of symptom onset not receiving rt-PA (non-rt-PA group), and patients admitted after time window for rt-PA (late group). Short-term clinical improvement was defined as the difference between NIHSS on admission minus NIHSS day 7. Favorable outcome was defined as mRS 0 - 3 and unfavorable outcome as mRS 4 - 6. Results: SUA measurements were available in 1136 patients. Clinical improvement was significantly higher in patients with high SUA levels at admission. After adjustment for possible confounders, SUA level showed a positive correlation with clinical improvement (r = 0.012, 95% CI 0.002-0.022, p = 0.02) and was an independent predictor for favorable stroke outcome (OR 1.004; 95% CI 1.0002-1.009; p = 0.04) only in the rt-PA group. Conclusions: SUA may not be neuroprotective alone, but may provide a beneficial effect in patients receiving thrombolysis.en_US
dc.language.isoengeng
dc.publisherBioMed Centraleng
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/2.0/eng
dc.titleSerum uri acid: neuroprotection in thrombolysis. The Bergen NORSTROKE studyen_US
dc.typePeer reviewed
dc.typeJournal article
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2011 Logallo et al; licensee BioMed Central Ltd.
dc.identifier.doihttps://doi.org/10.1186/1471-2377-11-114
dc.identifier.cristin877921
dc.subject.nsiVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Neurology: 752eng


Tilhørende fil(er)

Thumbnail
Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY